Sutro Biopharma Inc reports results for the quarter ended in December - Earnings Summary

Sutro Biopharma

28/03/2024 12:00

* Sutro Biopharma Inc  STRO.OQ  reported quarterly adjusted
earnings of 52 cents​​ per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of -68 cents.  The mean expectation of
ten analysts for the quarter was for a loss of 82 cents per
share. Wall Street expected results to range from -94 cents
to -71 cents per share.
    * Revenue rose 1,217.4% to $113.72 million from a year ago;
analysts expected $11.81 million. 
    * Sutro Biopharma Inc's reported EPS for the quarter was 52
cents​.
    * The company reported quarterly net income of $31.07
million.
    * Sutro Biopharma Inc shares had risen by 14.9% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Sutro Biopharma
Inc is $12.00 
This summary was machine generated from LSEG data March 28 at
12:00 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.82          0.52           Beat
 Sep. 30 2023      -0.74          -0.81          Missed
 Jun. 30 2023      -0.73          -0.64          Beat
 Mar. 31 2023      -0.81          -0.85          Missed